| Budget Amount *help |
¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We used human colon cancer cell line, Caco-2 cells, and established recombinant Caco-2 cells expressing EGFP under the control of human SIRT1 promoter. We monitored the changes in EGFP fluorescence after adding lactic acid bacteria by using flow cytometer, and identified T2102 strain as positive lactic acid bacteria. T2102 activated SIRT1, deacetylated and destabilized β-catenin. T2102 repressed hTERT expression and induced cellular senescence in Caco-2 cells. Furthermore, tumor suppressing activity of T2102 was evidenced by anchorage-independent growth and tumorigenicity.
|
